Phase 1 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been diagnosed (confirmed by a tissue test) with one of the following cancers that has spread or cannot be removed by surgery: gastrointestinal neuroendocrine tumors (GI NET), pheochromocytoma/paraganglioma (PPGL), small cell lung cancer (SCLC), kidney cancer, or certain head and neck cancers (nasopharyngeal carcinoma, olfactory neuroblastoma, or sinonasal neuroendocrine carcinoma).
• For kidney cancer, all types of primary kidney cancer are eligible.
• For GI NET, PPGL, and head & neck cancers, no specific previous treatment is required before joining.
• For SCLC, you must have received at least one previous standard treatment such as chemotherapy and/or immunotherapy.
• For kidney cancer (renal cell carcinoma specifically), you must have received at least one prior treatment including both an immune checkpoint drug and a VEGF-targeting drug; other kidney cancer types have different prior treatment requirements (confirm with trial site).
• You have NOT previously received a radioligand therapy as a main cancer treatment (prior external beam radiation is allowed).
• Your cancer has shown signs of getting worse on scans or through worsening symptoms within the past 3 years.
• A special scan has shown that somatostatin receptors are present on at least 50% of your visible tumors.
• You are 18 years of age or older.
• You are generally able to carry out daily activities with little or no restriction (confirm with trial site).
• Your blood counts, liver function, and kidney function are within acceptable ranges as determined by blood tests (confirm with trial site).
• If you have had brain tumors that were previously treated, there is no sign of them getting worse on recent scans.
• If you have new or growing brain tumors, you have no symptoms from them and do not need medication to manage those symptoms.
• If you are HIV positive, you are on effective treatment and your virus levels are undetectable.
• If you have had hepatitis B, your virus levels are undetectable.
• If you have had hepatitis C, you have completed curative treatment and your virus levels are undetectable.
• If you are able to become pregnant or father a child, you agree to use effective contraception during the study and for 6 months after the last dose.
• If you are breastfeeding, you are willing to stop from the start of treatment through 6 months after the last dose.
• You are able to understand the study and are willing to sign a consent form.

Who may not be able to join:

• You have taken part in another clinical trial and have not stopped that experimental treatment at least 28 days before starting this trial.
• You have received other cancer treatments within 28 days before starting (14 days for SCLC patients).
• You have had an allergic reaction to a drug that is similar in makeup to the study drug.
• You are pregnant (confirmed by a pregnancy test at screening).
• You have an abnormal heart rhythm reading (QTc over 450 ms) on an ECG at screening.
• You have another active or untreated cancer, except for certain minor skin cancers or early-stage cervical changes.
• You have other serious or uncontrolled health conditions that could increase your risk during the trial (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.